Drug Trial Radar · NCT01241552
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
Last checked: Nov 19, 2026Latest source record: Sep 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,452
Actual
Start
Oct 10, 2011
Primary completion
Dec 9, 2014
Study completion Dec 9, 2014
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 16, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate whether: 1) treatment with MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease Clostridium difficile infection (CDI) recurrence as compared to treatment with MK-6072 or MK-3415, 2) treatment with MK-3415A, MK-6072, or MK-3415, in addition to SOC antibiotic therapy will decrease CDI recurrence as compared to placebo, and 3) MK-3415A, MK-6072, and MK-3415 will be generally well tolerated in participants receiving SOC therapy for CDI as compared to placebo.
Conditions
- Clostridium Difficile Infection
Interventions
MK-3415Biological
A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
MK-6072Biological
A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
MK-3415ABiological
A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
PlaceboBiological
A single IV infusion of normal saline (0.9% sodium chloride)
SOCDrug
Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clostridium Difficile Infection (CDI) RecurrenceTime frame: Up to 12 weeks
- Percentage of Participants With One or More Adverse Events (AEs) During 4 Weeks Following InfusionTime frame: Up to 28 days
- Percentage of Participants With Any Drug-related AE During 4 Weeks Following InfusionTime frame: Up to 28 days
- Percentage of Participants With Any Serious Adverse Events (SAEs) During 4 Weeks Following InfusionTime frame: Up to 28 days
- Percentage of Participants With Any Serious Drug-related Adverse Events During 4 Weeks Following InfusionTime frame: Up to 28 days
- Percentage of Participants Who Discontinued Study Medication Due to an AE During 4 Weeks Following InfusionTime frame: Up to 28 days
- Percentage of Participants With Infusion-specific AEsTime frame: Up to 24 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.